The biotechnology industry is one of the most important industries in the world.
That’s especially true today as everyone is trying to develop a vaccine to stop the spread of COVID-19.
But just because coronavirus is getting all the headlines, that doesn’t mean other diseases have stopped existing and spreading altogether.
In fact, I feel like they’re being more overlooked now than ever.
That’s why I think investors should be scooping up these top three biotech stocks before the rest of Wall Street catches on…
The #3 Biotech Stock of 2020
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) is a biopharmaceutical company that develops clinical-stage small-molecule therapies for central nervous system disorders.
[finviz ticker=VNDA]On August 31, Vanda reported that the Phase III study of its drug, Tradipitant, was progressing and is expected to be completed in the first half of 2021.
Tradipitant has potential applications in the treatment of gastroparesis.
This a disease related to the stomach that an estimated 6 million people suffer from in the U.S. alone.
It’s also a possible means of accelerating clinical improvement in patients with COVID-19 pneumonia.
Investors would be wise to scoop up VNDA shares now before the FDA approves the Tradipitant next year and the stock pops.
The #2 Biotech Stock of 2020
Trillium Therapeutics Inc. (NASDAQ: TRIL) is a Canadian biotech firm that specializes in clinical-stage immuno-oncology treatments.
[finviz ticker=TRIL]It has preclinical programs and therapies that focus on treating cancer.
Trillium’s lead program is called “TTI-621” which is designed to act as a soluble decoy receptor, preventing CD47 (a high affinity receptor that plays a role in vascular development and angiogenesis) from delivering its inhibitory signal.
TRIL has a proprietary medicinal chemistry platform that uses fluorine chemistry. This permits the creation of new chemical entities with pharmacological properties.
The stock is up big time in 2020 – from $1.03 per share on Dec. 31, 2019 to $12.45 today.
That’s a 1,108% return for investors so far in 2020. And 2021 could deliver something similar.
The #1 Biotech Stock of 2020
The Guardian: “New pill could spell the end of aging.”
Take a look at this picture:
On the surface, this pill looks just like any other…
But don’t be fooled.
Inside is a revolutionary new technology that The Guardian reports could:
“spell the end of aging”
— The Guardian
And Scientific American says it could allow anyone that takes it to:
“stay young [forever]”
— Scientific American
This pill is set to completely change the lives of millions of Americans…
And because just one tiny Brisbane company has virtually monopolized this technology with 140 foolproof patents…
Investors who get in on the ground floor stand to become rich beyond their wildest dreams.
